Head and Neck cancer is 6th most common It shoul
Post# of 72440
It should be quick P3 trial for accrual of 150-200 patients in each arm
I am sure it will be a global trial not just in US
I think this is very positive development in IPIX history
I was worry FDA will ask for some additional data , sub-study or sub-group analysis etc. and they gave a quick OK for P3 and that itself is very positive as those FDA folks tend to be picky
Now we need BP to step in with generous offer ( deal) as P3's tend to be expensive
IMO obviously
cheers to all IPIX longs and very Merry Christmas